Lina Mora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lina Mora has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Rojas
Department of Genetics University of Cordoba Cordoba Spain
1 shared publication Alejandro Gonzalez
Centro Javeriano de Oncología, Pontificia Universidad Javeriana, Bogota, Colombia
1 shared publication- Ana María Urueña Serrano
Colombian Association of Medical Geneticists and Genomic Medicina (ACMGen), Bogotá, D.C, Colombia
1 shared publication - Camila Céspedes
Hospital Universitario San Ignacio
1 shared publication Catalina Forero
1 shared publication- Diana Torres
Institute of Human Genetics, Pontificia Universidad Javeriana, Bogotá, Colombia
1 shared publication
Latest Publications
- Open Access
- 15 August 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 705-719
Strengthening Medical Genetics and Genomic Medicine in Colombia: Progress, Challenges, and Strategic Opportunities
Colombia, an upper-middle-income country with over 52 million inhabitants, has made significant progress in consolidating medical genetics as a clinical specialty, with a growing presence in healthcare system, public health and academia. The development of specialized training programs, the establishment of a professional association, and the inclusion of genetic tests and treatments for rare diseases (RDs) within the health system have been key achievements. Birth defects (BD) remain one of the leading causes of infant morbidity and mortality, and alongside RDs, are recognized as public health priorities. Among regulatory milestones, the Newborn Screening (NBS) Law has strengthened early diagnosis efforts. Nevertheless, operational challenges persist, particularly in the nationwide implementation of genetic services, which remain concentrated in urban centers, creating significant gaps in rural areas. While technologies such as next-generation sequencing (NGS) are increasingly available in the private sector, a persistent fragmentation between molecular diagnosis and clinical care limits their impact. Furthermore, interoperability with health information systems is limited, and the country’s low density of medical geneticists restricts service availability. The Colombian experience underscores the value of institutional coordination, investment in diagnostic infrastructure, and the active role of patient organizations. Despite existing challenges, regional cooperation within Latin America emerges as a strategic opportunity to strengthen medical genetics and expand access for populations affected by RDs and complex genetic conditions.
- 15 August 2025
- Published by Springer Nature in Journal of Community Genetics
- Vol. 16 (6) , 705-719
Open AccessStrengthening Medical Genetics and Genomic Medicine in Colombia: Progress, Challenges, and Strategic Opportunities
Colombia, an upper-middle-income country with over 52 million inhabitants, has made significant progress in consolidating medical genetics as a clinical specialty, with a growing presence in healthcare system, public health and academia. The development of specialized training programs, the establishment of a professional association, and the inclusion of genetic tests and treatments for rare diseases (RDs) within the health system have been key achievements. Birth defects (BD) remain one of the leading causes of infant morbidity and mortality, and alongside RDs, are recognized as public health priorities. Among regulatory milestones, the Newborn Screening (NBS) Law has strengthened early diagnosis efforts. Nevertheless, operational challenges persist, particularly in the nationwide implementation of genetic services, which remain concentrated in urban centers, creating significant gaps in rural areas. While technologies such as next-generation sequencing (NGS) are increasingly available in the private sector, a persistent fragmentation between molecular diagnosis and clinical care limits their impact. Furthermore, interoperability with health information systems is limited, and the country’s low density of medical geneticists restricts service availability. The Colombian experience underscores the value of institutional coordination, investment in diagnostic infrastructure, and the active role of patient organizations. Despite existing challenges, regional cooperation within Latin America emerges as a strategic opportunity to strengthen medical genetics and expand access for populations affected by RDs and complex genetic conditions.
- Open Access
- 15 February 2022
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (2) , e151-e157
Prevalence ofBRCA1andBRCA2Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer
Pathogenic germline mutations in the BRCA1 and BRCA2 (BRCA1/2) genes contribute to hereditary breast/ovarian cancer (OC) in White/mestizo Colombian women. As there is virtually no genetic data on breast cancer (BC) in Colombians of African descent, we conducted a comprehensive BRCA1/2 mutational analysis of 60 Afro-Colombian families affected by breast/OC. Mutation screening of the complete BRCA1/2 genes for small-scale mutations and large genomic alterations was performed in these families using next-generation sequencing and multiplex ligation-dependent probe amplification analysis. Four pathogenic germline mutations, including one novel mutation, were identified, comprising 3 in BRCA1 and one in BRCA2. The prevalence of BRCA1/2 mutations, including one BRCA1 founder mutation (c.5123C>A) previously identified in this sample set, was 3.9% (2/51) in female BC-affected families and 33.3% (3/9) in those affected by both breast and OC. Haplotype analysis of 2 BRCA2_c.2701delC carriers (one Afro-Colombian and one previously identified White/mestizo Colombian patient with BC) suggested that the mutation arose in a common ancestor. Our data showed that 2/5 (40%) mutations (including the one previously identified in this sample set) are shared by White/mestizo Colombian and Afro-Colombian populations. This suggests that these 2 populations are closely related. Nevertheless, variations in the BRCA1/2 mutational spectrum among Afro-Colombian subgroups from different regions of the country were observed, suggesting that specific genetic risk assessment strategies need to be developed.
- 15 February 2022
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (2) , e151-e157
Open AccessPrevalence ofBRCA1andBRCA2Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer
Pathogenic germline mutations in the BRCA1 and BRCA2 (BRCA1/2) genes contribute to hereditary breast/ovarian cancer (OC) in White/mestizo Colombian women. As there is virtually no genetic data on breast cancer (BC) in Colombians of African descent, we conducted a comprehensive BRCA1/2 mutational analysis of 60 Afro-Colombian families affected by breast/OC. Mutation screening of the complete BRCA1/2 genes for small-scale mutations and large genomic alterations was performed in these families using next-generation sequencing and multiplex ligation-dependent probe amplification analysis. Four pathogenic germline mutations, including one novel mutation, were identified, comprising 3 in BRCA1 and one in BRCA2. The prevalence of BRCA1/2 mutations, including one BRCA1 founder mutation (c.5123C>A) previously identified in this sample set, was 3.9% (2/51) in female BC-affected families and 33.3% (3/9) in those affected by both breast and OC. Haplotype analysis of 2 BRCA2_c.2701delC carriers (one Afro-Colombian and one previously identified White/mestizo Colombian patient with BC) suggested that the mutation arose in a common ancestor. Our data showed that 2/5 (40%) mutations (including the one previously identified in this sample set) are shared by White/mestizo Colombian and Afro-Colombian populations. This suggests that these 2 populations are closely related. Nevertheless, variations in the BRCA1/2 mutational spectrum among Afro-Colombian subgroups from different regions of the country were observed, suggesting that specific genetic risk assessment strategies need to be developed.
- Open Access
- 1 September 2017
- Published by Instituto Mexicano del Seguro Social in Revista Urología Colombiana / Colombian Urology Journal
- Vol. 26 (3) , 164-168
Manejo transdisciplinario de pacientes con desórdenes del desarrollo sexual en Colombia. Limitantes para un manejo oportuno e integral
- 1 September 2017
- Published by Instituto Mexicano del Seguro Social in Revista Urología Colombiana / Colombian Urology Journal
- Vol. 26 (3) , 164-168
Open AccessManejo transdisciplinario de pacientes con desórdenes del desarrollo sexual en Colombia. Limitantes para un manejo oportuno e integral